First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
about
First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
First-week clinical responses ...... stroesophageal reflux disease.
@en
First-week clinical responses ...... stroesophageal reflux disease.
@nl
type
label
First-week clinical responses ...... stroesophageal reflux disease.
@en
First-week clinical responses ...... stroesophageal reflux disease.
@nl
prefLabel
First-week clinical responses ...... stroesophageal reflux disease.
@en
First-week clinical responses ...... stroesophageal reflux disease.
@nl
P2093
P2860
P356
P1476
First-week clinical responses ...... stroesophageal reflux disease.
@en
P2093
Chao-Hung Kuo
Cheng-En Tsai
Chih-Chien Yao
Chih-Fang Huang
Chih-Ming Liang
Deng-Chyang Wu
Hsing-Ming Wang
Keng-Liang Wu
Ming-Te Kuo
P2860
P304
P356
10.3748/WJG.V23.I47.8395
P407
P577
2017-12-01T00:00:00Z